Objective To evaluate the effect of sacubatre/valsartan on echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction (HFrEF).
Methods Totally 50 patients with chronic HFrEF from July 2018 to December 2020 were selected as study objects. All the patients were conducted with clinical examination and assessment of echocardiography and color Doppler ultrasound before starting to use sacubitril/valsartan, and the same examinations were repeated at 3 months. The cardiac function was evaluated by New York Heart Association (NYHA) classification.
Results In the course of study, 7 patients were excluded due to the intolerance of sacubitril/valsartan treatment, and finally 43 patients completed the study. There were significant differences in left ventricular ejection fraction (LVEF), left ventricular end systolic volume (LVESV), left ventricular end diastolic diameter (LVEDD), integral velocity time (IVT) and right ventricular systolic pressure before and after treatment in 43 patients (P < 0.01). After treatment, 19 cases (response group) had response to ultrasound and 24 cases (non-response group) had no response to ultrasound. There were significant differences in left ventricular end diastolic volume (LVEDV), LVESV, LVEDD and mitral regurgitation ratio between the two groups (P < 0.05 or P < 0.01). No effects on left ventricular diastolic function or right ventricular parameters were observed in cases with sacubitril-valsartan response.
Conclusion In patients with HFrEF, sacubitril/valsartan can significantly improve left ventricular systolic remodeling, and responders show mild left ventricular remodeling and lower mitral regurgitation ratio.
DownLoad: